Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11361MR)

This product GTTS-WQ11361MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11361MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15774MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ8985MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ11111MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ11023MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ9479MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ5334MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ13035MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ14056MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW